TWM
LGND icon

Tripletail Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Tripletail Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
+355
New +$83.6K 0.13% 113
2026
Q1 		– Sell
-710
Closed -$130K – 264
2025
Q4 		$130K Hold
710
– – 0.16% 97
2025
Q3 		$129K Buy
+710
New +$106K 0.15% 100

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tripletail Wealth Management's LGND Position: Q2 2026 in Review

Tripletail Wealth Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 355 shares worth $113K. The stake represents 0.13% of the portfolio and ranks #113 among its holdings. This is a return to the name: Tripletail Wealth Management previously reported a position in LGND as recently as Q4 2025.

Tripletail Wealth Management first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. The position peaked at $130K in Q4 2025. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Tripletail Wealth Management held 355 shares of Ligand Pharmaceuticals worth $113K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Tripletail Wealth Management position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.13% of Tripletail Wealth Management's portfolio in Q2 2026, its #113 holding.
  • Tripletail Wealth Management first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Tripletail Wealth Management's Ligand Pharmaceuticals position peaked at $130K in Q4 2025.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Tripletail Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.